APACMed’s Chairman, John Collings, welcomes delegates to MedTech Forum. He shares more about the theme of Patient Futures 2025 and our continued march towards the Patient Futures 2025 vision.
John Collings
Chairman,
Asia Pacific Medical Technology Association Ltd.
Home to 60% of the world’s population, there is much aspiration in Asia Pacific for an activated patient community. Studies show that activated patients demonstrate improved health outcomes while lowering the cost base by more than 30%. So, what is the potential for a patient-centric reality in the region, and where are the remaining gaps? Elisabeth shares leading-edge visions for patients and the healthcare ecosystem.
Elisabeth Staudinger
Vice-Chairman,
Asia Pacific Medical Technology Association Ltd.
Managing Board Member &
Head of Asia Pacific,
Siemens Healthineers
The terminology around “patient centricity” was introduced in the 1980s through the increasing proliferation of technologies which allowed for care to be delivered in other settings apart from only the hospital. Fast forward to 2022, patient centricity has become a daily conversation - from further decentralization of care models to advancements in digital tools like remote care management, as well as the rise in the patient voice. How far has Asia Pacific come in making patient centricity a reality, what do the leading models look like, and how can public-private sector work together to drive more progress? Our panel of experts will share real-world use cases from their respective experiences with Patient-Centric Care Models, ranging from care provision to patient activation to medical technologies.
Aaron Villaruz
Vice President,
DePuy Synthes, Asia Pacific, the Orthopaedics company of Johnson & Johnson
Andrew Currie
General Manager,
Fresenius Kidney Care, Asia Pacific
Chief Executive Officer,
Cura Day Hospitals Group
Rami Karjian
Chief Executive Officer,
Medically Home
Ratna Devi
Director,
Patient Academy for Innovation and Research (PAIR)
What does "patient futures" look like in connected care settings? In this fireside chat, hear about the innovations that enable smart, safe, patient-centred care. Through use cases shared, Joseph outlines how the adoption of technology and innovation with features of connectivity and analytics can support the transformation of care, including decentralized care settings. Joseph and Feras will further discuss the level of readiness for adopting connected care solutions in Asia Pacific and how can the industry accelerate progress towards the vision of patient futures through connected care.
Joseph (Joe) Smith
Chief Scientific Officer,
Becton Dickinson
Feras Mahdi
Senior Principal & Head of MedTech
APAC Regional HQ & SEA,
IQVIA
Despite the ambitions around patient-centric care models and the enablement of technology for opportunities like remote care management, often the bottleneck in adoption comes down to financial constructs which are used to control access. The point is particularly relevant in Asia Pacific where some 1.6 billion people still lack access to even the most basic healthcare services. Our experts discuss how public and private sector can continue to collaborate on viable and equitable programs to deliver on the promise of health-for-all for patients. They will share their respective experiences with access and financial security, ranging from cross-cutting financial innovations in areas such as digital health and private insurance, to disease-specific access ambitions in the likes of liver cancer and diabetes.
Giles Newmarch
Senior Investment Officer,
Health and Education,
International Finance Corporation
Jonathan Larsen
Chief Innovation Officer,
Ping An Group
Chairman and Chief Executive Officer,
Ping An Global Voyager Fund
Slobodan Radumilo
Senior Vice President & President International,
embecta
Chair Diabetes Sector Group,
MedTech Europe
Varun Veigas
Vice-Chair, Reimbursement Group, Digital Health,
Asia Pacific Medical Technology Association Ltd.
Leader, Policy and Strategic Partnerships, Health Policy and Patient Access,
Roche Diagnostics Asia Pacific
Technology has been an enabler for patients that will make the difference in wide-scale adoption of model shifts. While COVID-19 has been a boom for concepts like digital health and remote care management, the realities of equity in technology access and privacy concerns therein remain omnipresent. Breaches in healthcare data now exceed any other sector, leading to challenges of trust in Asia Pacific.
The Metaverse is touted to have a significant and comprehensive impact on healthcare. Metaverse will facilitate research and development proficiencies to bring about technological advancements in healthcare facilities by tackling the problem of geographical limitations, promote virtual wellness and fitness, and much more.
Shafi’s keynote presentation will touch upon safeguarding the patient amidst the evolution of technology and overcoming challenges of data privacy and trust. He will also share how VR and AR in healthcare improves patient engagement and outcomes.
Shafi Ahmed
Chief Medical Metaverse Officer,
Aimedis – eHealth on Blockchain
In the earlier sessions, various aspects of Patient Futures – care models, technology, access were discussed. Often the critical success factor in transforming these aspects into reality relies on patient empowerment. Our experts reflect on how our societies empower people to take charge of their healthcare journeys: as patients for themselves and as caregivers to others. They will share their views on whether COVID-19 has increased the momentum to greater patient empowerment or that it continues to be an overlooked point in our broader policy reform and innovation adoption efforts.
Elizabeth (Liz) Carnabuci
Vice President & Managing Director,
Australia & New Zealand, and Diabetes Group, APAC,
Medtronic
Maria Fatima Garcia-Lorenzo
Co-Founder,
Philippine Alliance of
Patients' Organization
Probir Das
Board of Director,
Asia Pacific Medical Technology Association Ltd.
Aside from broader 2030 objectives like achieving Universal Health Coverage, the COVID-19 pandemic years have been particularly challenging for the WHO, countries, private sector and families.
Soumya shares more about the WHO’s role during the pandemic, current initiatives underway (such as the Digital Health Taskforce) and her personal reflections from a storied journey ranging from being the daughter of a revolution leader to serving populations in need as a pediatrician.
Following Soumya’s keynote session, Lance and Mick will elaborate on how regional bodies (public and private) typically interact with such international NGOs. They will discuss lessons learned over the past couple of years and given the unique needs of APAC, their views on where efforts need to be prioritized to achieve the “Patient Futures 2025” ambition.
Lance Little
Managing Director, Region Asia Pacific, Roche Diagnostics Asia Pacific Pte Ltd
Chris Hardesty
Strategic Advisor,
Asia Pacific Medical Association Ltd.
Mick Reid
Former Director General of Health, New South Wales & Queensland Australia
Continuing the theme of bringing the morning’s discussions and use cases together for the sake of more integrated patient care models, this panel dialogue is meant to be a vulnerable one.
Healthcare in Asia Pacific is still disparate, from mature UHC and technology adoption to billions of people who lack access to even the most essential services. We must be open about the remaining barriers to achieving the Patient Futures vision in order to find practical solutions. Our panellists identify pain points that are hindering our progress to greater equity in Patient Futures.
Aparna Mittal
Founder and Chief Executive Officer,
PatientsEngage
James Lim
Treasurer & Board of Director,
Asia Pacific Medical Technology Association Ltd.
ex-Executive Vice President & President, Greater Asia, BD
Simon Gordon
Chief Commercial Officer,
Accredify
Vijay Subramaniam
General Manager,
Imaging - ASEAN, Korea and ANZ,
GE Healthcare
Moderator
Omair Azam
Associate Director,
Crowell & Moring International
In the final dialogue session of the day, our panellists discuss how can stakeholders come together to drive meaningful impact for integrated care in Asia Pacific. Focusing on realizing Patient Futures 2025, they envision where the MedTech industry can realistically land over the next three years and reflect backwards about what it takes to get there.
Makoto (Mark) D. Kawai
Director Government Affairs,
Zimmer Biomet
Mick Reid
Former Director General of Health, New South Wales & Queensland Australia
Ratna Devi
Director,
Patient Academy for Innovation and Research (PAIR)
Xu Ming
Dean, Department of Global Health,
School of Public Health, Peking University
Moderator
Farhana Nakhooda
Board of Director,
Asia Pacific Medical Technology Association Ltd.
General Manager &
Senior Vice President,
Health Catalyst Asia Pacific
The rising prevalence of chronic diseases in Asia Pacific poses key public health challenges. MedTech companies are uniquely positioned to play a role in addressing these needs with innovative and integrated service offerings, in more ways than one. The Health Services Working Group will be launching their second report: Chronic Disease Management: The Case for MedTech Health Services.
Christoph Liesche
Head of Public & Government Affairs Asia Pacific,
Fresenius Medical Care
Traditionally viewed as product manufacturers, MedTech companies have increasingly innovated beyond the product into developing patient-facing services and solutions with innovative care delivery models. Concurrently, technology companies have strong offerings in the digital health services space as well. With innovation and disruption abound, patient expectations are rising for traditional service providers. This session provides candid perspectives from service providers, new and old, on the value of patient-centric service delivery and challenges for service innovation.
Christoph Liesche
Head of Public & Government Affairs Asia Pacific,
Fresenius Medical Care
GA Vice-Chair, APACMed GAMA Committee
Fabian Mueller
Health Access Strategy Lead, APAC,
Roche Diagnostics
Ryan Kim
Partner,
Kakao Ventures
Moderator
Stephen Sunderland
Partner, Head of Southeast Asia Healthcare and Life Sciences,
L.E.K. Consulting
APACMed China recently held an Expert Dialogue with Tsinghua University on 28 Aug 2022 on Health Services beyond Hospitals. Hear from our Country Lead, Ms Alicia Chang, on the perspectives of clinical KOLs advocating for innovative models of care at community and home, and how medical technology can enable chronic disease management for the population in China.
Alicia Chang
Country Lead, China
Asia Pacific Medical Association Ltd.
Prevention and early detection through diagnostics plays a pivotal role in lifting the burden of the healthcare systems. As diagnostics techonology accelerates development of both specialised precision testing, as well as decentralised point of care (POC) testing, they play a crucial role in strengthening health systems. In this panel, we explore two use cases (cardiovascular disease and infectious diseases) through the perspectives of senior clinical practicioners in Singapore and Australia.
Alex Cook
Associate Professor & Vice Dean (Research),
National University of Singapore, Saw Swee Hock School of Public Health
Martin Than
Director, Emergency Medicine Research & Emergency Medicine Specialist,
Christchurch Hospital, New Zealand
Viva Ma
Director of Strategic Access,
Public Affairs, Greater Asia,
Becton Dickinson Holdings Pte Ltd
The COVID-19 pandemic has exposed structural vulnerabilities in “just-in-time” global supply chains. In response, health systems across the region are seeking to strengthen supply chain resilience and strategic procurement policies. Overcoming supply chain and procurement challenges presents a valuable opportunity for MedTech to promote collaboration and ensure patient access to treatment is prioritised. Join us for this panel discussion to learn how MedTech industry can partner governments to overcome these critical challenges.
Sui-Leng Khoo
Vice President, APAC Deliver Operations,
Johnson & Johnson MedTech
Xue Bai
Director, Supply Chain, Asia,
embecta
Moderator
Stephen Sunderland
Partner, Head of Southeast Asia Healthcare and Life Sciences,
L.E.K. Consulting
As emerging technologies drive new business and service models, regulations should also match the pace of such rapid innovation. This ensures that citizens have access to the best technologies, thereby creating an enabling ecosystem for healthcare and innovation to flourish.
Lance Little
Managing Director, Region Asia Pacific, Roche Diagnostics Asia Pacific Pte Ltd
Reliance is an essential and pragmatic concept to increase the efficiency of the global regulatory oversight of medical products by national regulatory authorities. In the longer term, regulatory reliance could be the driver for achieving harmonization and convergence in APAC as stakeholders continue to collaborate closely with each other and share best regulatory practices continuously and consistently. This will ensure the availability of safe and effective medical devices in the region in the shortest time possible. In the midterm, the goal is to build an extensive network for cooperation and regulatory reliance in APAC. APACMed is currently working closely with Regulatory Authorities to explore the possibility of expanding the regulatory reliance network in APAC, whether as relying markets, reference markets or both. This panel discussion will act as an impetus to position Regulatory Reliance as a pragmatic and effective tool to accelerate patient access to medical devices in APAC without compromising on the safety, and performance of the products.
John Lim
Executive Director,
Duke-NUS CoRE
Senior Advisor,
Ministry of Health, Singapore
Lupi Trilaksono
Team Lead, Medical Device Local Content and Production Improvement , Directorate of Pharmaceutical and Medical Devices Resilience,
Ministry of Health, Republic of Indonesia
Maria Cecilia C. Matienzo
Director IV, Center for Device Regulation, Radiation Health, and Research,
Food and Drug Administration, Philippines
Sethuraman Rama
Director, Medical Devices,
Health Products Regulation Group,
Health Sciences Authority Singapore
Tracey Duffy
Chairperson, IMDRF; First Assistant Secretary, Medical Devices & Product Quality Division, Therapeutic Goods Administration (TGA Australia)
Yasha Huang
Head of Regulatory Policy Asia Pacific,
Global Regulatory Policy & Intelligence,
Roche Diagnostics
Chairperson, In-Vitro Diagnostics (IVD) Working Group & Vice-Chair, Regulatory Group, Digital Health,
Asia Pacific Medical Technology Association Ltd.
The global pandemic has had a significant and transformative impact on health care, particularly on those involved in developing COVID-19–related treatments, medical devices, and vaccines, and others who ensure that already-approved medical products remain available to patients. While many regulatory measures have been introduced temporarily as a response to the unprecedented crisis, there are opportunities for leveraging an understanding from these approaches in order to collectively achieve more efficient and fit-for-purpose regulatory systems for new and innovative technologies coming up globally and further future-proof the regulatory environment. In light of this, this session aims to highlight emerging trends in healthcare and the impact of these trends in the region, evaluate and offer some reflection on current impediments to the adoption of innovative technologies and key learnings to further improve regulatory agility during the new normal health era.
Ahmad Sharif Bin Hambali
Chief Executive Officer, Medical Device Authority, Malaysia
Fikriansyah Bin Irman
Senior Medical Device Reviewer
Directorate of Medical Devices Evaluation,
Ministry of Health, Republic of Indonesia
Jinwon Seo
Deputy Director, MD Policy Division,
MD Safety Bureau,
Ministry of Food and Drug Safety, Korea
Real world data (RWD) indicate patient and healthcare data generated and collected from sources outside of traditional clinical trials, such as electronic health records, wearables, in-home monitoring, health surveys, insurance claims, patient registries, and beyond. With the increasing digitalization of healthcare, evidences generated through RWD become an actionable and valuable tool to inform regulators and policymakers, and support them to take decisions relative to product approval and reimbursement.
In the recent paper “Advancing Real World Evidence in APAC – Key Considerations for Policymakers”, APACMed explored the state of policy innovation regarding the use of RWE for regulatory and reimbursement decision-making.
In this fireside chat, we will discuss with Tracey Duffy, First Assistant Secretary at Therapeutic Good Administration of Australia, and learn about the views and strategy of the Australian government when it comes to RWE utilisation.
Tracey Duffy
Chairperson, IMDRF; First Assistant Secretary, Medical Devices & Product Quality Division, Therapeutic Goods Administration (TGA)
Shweta Bhardwaj
Chair, Digital Health India
Center of Excellence,
Asia Pacific Medical Technology Association Ltd.
Director Global Digital & R&D Policy,
Johnson & Johnson
Healthcare is becoming more digital and connected, increasing the need for cybersecurity and protecting information. Digital adoption has led to increased collection of personal and financial data about customers. Making them more attractive targets for cybercriminals.
In this session, you will learn how a medical device manufacturer would react in a real vulnerability or breach, identify strengths and weaknesses in their plan, and promote response readiness within the manufacturer’s organization.
Christian Fitsch
Vice President,
Chief Legal Counsel APAC,
Stryker
Vice Chair, Legal Ethics and Compliance Committee,
Asia Pacific Medical Association Ltd.
Danny Van Kersschaver
Chair, Digital Health,
Japan Center of Excellence,
Asia Pacific Medical Association Ltd.
Business Development Director Patient Monitoring/IT for Japan and Korea, Marketing Manager Patient Monitoring/IT for Japan,
Draeger
Mary Kiang
Chair, Digital Health ASEAN
Center of Excellence,
Asia Pacific Medical Association Ltd.
South Korea has been leading the development of digital health technologies (DHTs) in Asia Pacific and put significant effort into fostering DHTs over the past few years. The Ministry of Food and Drug Safety (MFDS) has been publishing regulatory review guidelines for several DHTs and recently announced the expedited market access process by collaborating with two other agencies: National Evidence-based Healthcare Collaborating Agency (NECA, HTA agency) and the Health Insurance Review and Assessment Service (HIRA).
With the escalated interest in the digital health field, especially digital therapeutics (DTx), the demand for national health insurance (NHI) coverage is also increasing. In June 2022, HIRA has published a research report on the “National Health Insurance Coverage Application for Digital Therapeutics” . The report presented a NHI coverage application plan for DTx based on the literature review, domestic and foreign policy case study, for instance, case studies of the U.S., U.K. and Germany, and the results of interviews with domestic stakeholders. The main findings of the research are well described including
the scope of coverage for DTx,
the pathway for health technology assessment known as ‘Innovative Health Technology Assessment’ track,
criteria for NHI coverage determination, and
payment determination and pricing rule.
In this session, Dr. Jang, who is in charge of medical technology coverage determination at HIRA, will present the current policy direction of NHI for DHTs focusing on DTx and key findings of the research. He will also share his thought about future of DTx (or DHTs) in South Korea.
Jun-Ho Jang
Director of Medical Technology
Listing Division,
Health Insurance Review and Assessment Service (HIRA), South Korea
Sang-Soo Lee
Chair, Market Access Group, Government Affairs & Market Access,
Asia Pacific Medical Association Ltd.
Senior Health Care Economics & Government Affairs Director,
Medtronic North Asia (Korea and Japan)
Chair of Reimbursement Committee,
Korea Medical Devices Industry Association (KMDIA)
Hear from the Digital Health Committee leadership team as they launch new publications and initiatives to advance digital health in APAC. They will cover topics on ensuring fast and safe approval of life-saving digital health technologies, to ensuring better and more equitable access for patients, to supporting optimal utilisation.
Anh Bourcet
Director, Market Access APAC,
Abbott
Arif Fahim
Chair, Reimbursement Group, Digital Health,
Asia Pacific Medical Association Ltd.
Regional Director, Health Economics & Reimbursement Asia Pacific,
Abbott
Manan Hathi
Chair, Regulatory Group,
Digital Health,
Asia Pacific Medical Technology Association Ltd.
Senior Manager Regulatory Affairs,
Stryker
Roberta Sarno
Director, Digital Health Committee,
Asia Pacific Medical Association Ltd.
Varun Veigas
Vice-Chair, Reimbursement Group, Digital Health,
Asia Pacific Medical Technology Association Ltd.
Leader, Policy and Strategic Partnerships, Health Policy and Patient Access,
Roche Diagnostics Asia Pacific
Two years ago, the APACMed Digital Health Committee was created to help optimising policies for digital health in the Asia Pacific through private-public collaborations.
Today, APACMed is supporting the MedTech ecosystem across the entire digital health journey, from regulatory approval to reimbursement and use.
During this session, Fabio La Mola, partner at Bain & Company, will share the most strategic, emerging trends shaping the future of digital health, and moderate a discussion on the top priorities for APACMed in the near future.
Anh Bourcet
Director, Market Access APAC,
Abbott
Arif Fahim
Chair, Reimbursement Group, Digital Health,
Asia Pacific Medical Association Ltd.
Regional Director, Health Economics & Reimbursement Asia Pacific,
Abbott
Paul Chua
Vice-Chairman, Cybersecurity Group, Digital Health,
Asia Pacific Medical Association Ltd.
Cybersecurity Officer, Greater Asia,
BD
Yasha Huang
Head of Regulatory Policy Asia Pacific,
Global Regulatory Policy & Intelligence,
Roche Diagnostics
Chairperson, In-Vitro Diagnostics (IVD) Working Group & Vice-Chair, Regulatory Group, Digital Health,
Asia Pacific Medical Technology Association Ltd.
A warm welcome to the audience to inspire the program for the day. Speaker will outline the ambition of the refreshed APACMed Start-ups initiative, and share personal reflections on the importance of this topic for the industry in the Asia Pacific.
Chris Hardesty
Strategic Advisor,
Asia Pacific Medical Technology Association Ltd.
Our speakers will share trends and perspectives about corporate investing, including in the medtech industry. They will also outline the opportunity for capability , inspiring corporates to get more involved. In addition, there will be time to interact with the audience, providing advice for how the wider community can collaborate ahead.
Fabio La Mola
Partner, APAC Healthcare,
Bain & Company
Michael Egan
Expert Partner, Innovation & Design
Bain & Company
Continuing from the prior session, the panel will outline their major priorities as corporate investors pertaining to medtech in the Asia Pacific. Discussion covers the challenges and successes of working with start-ups and other investors, as well as the learnings therein. There will be time to interact with the audience too, offering advice for collective capability building.
Ashley Wittorf
Head of Business Development,
Asia Pacific
Johnson & Johnson MedTech
Joseph (Joe) Smith
Chief Scientific Officer,
Becton Dickinson
Purushottam Awasthi
Head of Strategy & Business Development, APAC
Siemens Healthineers
Sudeep Dhariwal
Senior Director Strategy &
Business Development and
Channel Management APAC,
Medtronic
Describing the APACMed collaboration undertaken for the initial batch of start-ups. Claudia will share learnings from this process, as well as other external reflections and the plan ahead. There will be time to interact with the audience too, inspiring more stakeholders to get involved.
Claudia Zeisberger
Senior Affiliate Professor of Entrepreneurship & Family Enterprise,
INSEAD
Founder and Academic Co-Director,
Global Private Equity Initiative
Exchange on the major priorities of institutional investors as it pertains to medtech in the Asia Pacific. This session will cover the challenges and successes in working with start-ups (and other investors), including the learnings therein. There will be time to interact with the audience too, fostering an environment for start-up and investor connectivity.
Claudia Zeisberger
Senior Affiliate Professor of Entrepreneurship & Family Enterprise,
INSEAD
Founder and Academic Co-Director,
Global Private Equity Initiative
The top three APACMed Start-up members will demonstrate their "perfect pitching", as guided by Claudia. The start-ups will share a pitch, then exchange with others about the experience. In addition, all top 10 Start-up companies will be recognized for their efforts.
Claudia Zeisberger
Senior Affiliate Professor of Entrepreneurship & Family Enterprise,
INSEAD
Founder and Academic Co-Director,
Global Private Equity Initiative
Paul summarizes observations from the day and outlines the plan ahead. This is followed by a networking luncheon.
Paul Grand
Chief Executive Officer,
MedTech Innovator
*Program is subject to changes at the discretion of Asia Pacific Medical Association Ltd.
APACMed provides a unifying voice for the medical devices and in-vitro diagnostics industry in Asia Pacific. Founded in 2014, APACMed strives to promote innovation and impact policy that advances healthcare access for patients.
